Drug Trial Radar · NCT00289614
Patients With Renal Impairment and Diabetes Undergoing Computed Tomography (CT)
Last checked: Nov 19, 2026Latest source record: Jan 7, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
350
Planned (sponsor's estimate)
Start
Jan 2006
Primary completion
Not stated
Study completion Apr 2007
Sponsor
- Lead sponsor
- Bracco Diagnostics, IncIndustry
- Sponsor type
- Industry
- First posted
- Feb 10, 2006
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The main purpose of this study is to compare the incidence of contrast induced nephrotoxicity following the administration of Isovue (iopamidol) or Visipaque in diabetic patients with moderate to severe chronic renal impairment undergoing clinically indicated contrast enhanced multidetector computed tomography (MDCT). Serum creatinine will be measured before and up to 48-72 hours post dose.
Conditions
- Kidney Diseases
Interventions
Iopamidol 370 mgI/dLDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Increase in serum creatinine (SCr) at 48-72 hours post dose
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Bracco Diagnostics, Inc.
Princeton, New Jersey
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.